Both cohorts were also similar in terms of other AML characteristics at the time of diagnosis, including white blood cell (WBC) count, peripheral blood and bone marrow blasts, lactate dehydrogenase (LDH) levels, additional cytogenetic aberrations otherwise considered adverse according to ELN criteria, and selected co-mutations, including KIT, FLT3-ITD and NRAS mutations. The gene discussed is NRAS; the disease is acute myeloid leukemia.